NCT00791011 - Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

August 31, 2011

Conditions

Hodgkin's LymphomaLow Grade LymphomaLymphomaMantle Cell LymphomaNon-Hodgkin's LymphomaDiffuse Large Cell Lymphoma

Interventions

DRUG

AMG 655

AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).

OTHER

Vorinostat

Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).

OTHER

Bortezomib

A dipeptide boronic acid analogue with antineoplastic activity.